Merrimack Pharmaceuticals Inc (NASDAQ: MACK) shares rose 0.6% to $5.53 after the company revealed that the ONIVYDE regimen has received a positive CHMP Opinion in the European Union. Share volume was 463,000, compared to an all-day average of 1.7 million
